Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ashley Ward, MD
MacroGenics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
20 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic - Az
Scottsdale, Arizona, United States
- Christiana Care Health Services, Inc.
Newark, Delaware, United States
- Mayo Clinic - Fl
Jacksonville, Florida, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Norton Cancer Institute Research Program
Louisville, Kentucky, United States
- University of Maryland Greenbaum Cancer Center
Baltimore, Maryland, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- South Texas Accelerated Research Therapeutics, Llc - Midwest
Grand Rapids, Michigan, United States
- Mayo Clinic - Mn
Rochester, Minnesota, United States
- Nebraska Cancer Specialists
Omaha, Nebraska, United States
- Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Columbia University Medical Center
New York, New York, United States
- Gabrail Cancer Institute
Canton, Ohio, United States
- Hospital of the University of Pennsylvania/abramson Cancer Center
Philadelphia, Pennsylvania, United States
- University of Pittsburg
Pittsburgh, Pennsylvania, United States
- Rhode Island Hospital
Providence, Rhode Island, United States
- Greenville Health System
Greenville, South Carolina, United States
- Mary Crowley Cancer Research Center
Dallas, Texas, United States
- South Texas Accelerated Research Therapeutics, Llc
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2015
- Primary completion
- 18 Aug 2021
- Completion
- 18 Aug 2021
- Last update posted
- 11 Aug 2025
- Registered enrollment
- 146
- Registry id
- NCT02475213
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.